Sanofi's expanded alliance with Regeneron has potential implications for both companies.
Sanofi's announcement about its expanded alliance with Regeneron and new pipeline data has caught the attention of the health care sector. This partnership could significantly influence Regeneron's future, although the exact outcomes are still uncertain. In the last trading session, Sanofi's stock closed at US$40.15, showing a slight increase of 0.07% for the day, but a decline of 1.08% over the past week and 6.79% over the last month. Year-to-date, the stock has decreased by 11.96%.
Advertisement
Sanofi ADR
SNY.US
SNY.US
Sanofi ADR
WealthAwesomeMarket cap
$96.32B
P/E
21.2x
Div. yield
10.41%
Div. / share
$4.12
52W high
$49.91
52W low
$39.18
1W change
-1.08%
Beta
0.28
Analyst Price Targets
Based on 10 analysts covering SNY · as of Oct 9, 2026
Wall Street analysts forecast SNY stock price to rise 188.9% over the next 12 months.
Consensus
Buy4.00 / 5.00
Avg. Target
C$53.61
+188.9% Upside
Previously C$53.72 on Oct 5, 2026
Current Price
C$18.56
Last close
Analyst Breakdown (10 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SNY's historical volatility
30-Day Vol
17.3%
Annualized
90-Day Vol
24.4%
Annualized
Trend (90d)
-34.6%
Annualized drift
90d Mean
C$35.56
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$38.61 | C$36.38 – C$40.98 |
| 60 trading days | C$37.05 | C$34.06 – C$40.31 |
| 90 trading days | C$35.56 | C$32.08 – C$39.42 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on developments from the expanded alliance and pipeline data for potential market implications.
Sanofi's stock closed at US$40.15 with a market cap of approximately US$96.3 billion.
Despite a modest daily gain of 0.07%, Sanofi's stock has faced a significant decline of nearly 12% year-to-date.
Bull case
The expanded alliance could enhance Regeneron's product offerings and strengthen its position in the market. This collaboration may lead to new opportunities in drug development and commercialization, potentially boosting Regeneron's competitiveness.
Bear case
Sanofi's current market performance indicates skepticism, as reflected in its nearly 12% decline year-to-date. Investors may be cautious about the long-term benefits of the expanded alliance given the stock's recent performance.
Details of the Expanded Alliance
Advertisement
Sanofi's expanded alliance with Regeneron aims to improve collaboration in drug development and commercialization. This announcement coincides with new pipeline data, suggesting advancements in their shared therapeutic areas. While specifics about project timelines and expected outcomes haven’t been disclosed, this partnership could open up a range of new opportunities for both companies. Investors will be looking for clarity on how these developments will impact market performance.
Market Performance Overview
Sanofi's stock closed at US$40.15, reflecting a slight daily increase of 0.07%. However, its year-to-date performance shows a decline of 11.96%, with a weekly drop of 1.08% and a monthly decrease of 6.79%. The stock is currently trading at 7.1% below its 50-day moving average of US$43.22 and 10.7% below its 200-day moving average of US$44.97. Additionally, the stock is positioned within a 52-week range of US$39.18 to US$49.91, indicating it is near the lower end of that range. The trading volume for the latest session was 31,569 shares, which is only 0.98 times the 20-day average volume of 3,056,452 shares.
Looking Ahead: What to Watch
Moving forward, investors should closely monitor any updates related to the expanded alliance and pipeline developments. The potential for new products or improved market strategies could significantly influence Sanofi's stock performance. Analysts currently have an average target price of US$53.61, suggesting an implied upside of 33.5% from the last close. Given the ongoing developments, market participants will be attentive to how these initiatives may reshape the company's competitive standing in the health care sector.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
